Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel in Advanced Lung Cancer

Description

According to the results from a recent phase III trial, reported in the Journal of Thoracic Oncology, researchers compared solvent-based paclitaxel with nanoparticle albumin bound (nab) paclitaxel in the treatment of patients with advanced non–small cell lung cancer (NSCLC). Yasuto Yoneshima, MD, PhD, and colleagues from the Graduate School of Medical Sciences, Kyushu University in Fukuoka, Japan, found that treatment with nab-paclitaxel was noninferior compared with docetaxel in regard to overall survival and superior in regard to progression-free survival and objective response rate.